MissionIR Articles
-
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s CIO Discusses Curing Cancer with AI on DojoLIVE! Interview
POAI subsidiary Helomics exec discusses the company’s quest to fight cancer Helomics tapping into the fast growing, billion-dollar AI in drug discovery market Pittsburgh-based company has been building foundational groundwork in cancer drug response profiling…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Helomics Provide Key Insight to Personalized Cancer Treatment
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, lives by the motto: Cancer is personal; we believe therapy should be too. The company’s subsidiary Helomics builds AI-driven…
-
Predictive Oncology Inc. (NASDAQ: POAI) Confirms Attendance at Upcoming LD 500 Microcap Investor Conference
Predictive Oncology presenting at upcoming LD 500 investor conference Investor event will take place Sept. 1-4, 2020 and will feature 500 handpicked companies from across North American listed micro-cap universe Predictive Oncology specializes in applying…
-
MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Recent Board Appointments Combine Deep Experience, Expertise to Drive Strategic Vision
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, recently announced board appointments to align expertise with the company’s strategic vision. These recently appointed board members — Dr.…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Slated for Presentation at Prestigious LD 500 Virtual Investor Conference
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that company executives will be presenting at LD Micro’s elite LD 500 Virtual Investor…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) and TumorGenesis Advancing Path Toward Patient-Specific Treatments
Predictive Oncology (NASDAQ: POAI), together with its TumorGenesis subsidiary, has achieved significant breakthroughs in applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Earlier in June, TumorGenesis, which is developing a new…
-
Predictive Oncology Inc.’s (NASDAQ: POAI) Exclusive Resources Provide Personal Profiling, Tools to Improve Patient Outcomes
POAI, Helomics builds AI-driven models that predict drug response, patient outcome Company tests patient tumor, generates comprehensive picture that oncologists use to individualize therapy Key to individualized insight is POAI’s Tumor Drug Response Profiling (“TDRP”)…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Lands Milestone Contract with Major Pharmaceutical Company
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its Soluble Biotech division has finalized its first major contract since being acquired by…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Sale of 8 Skyline Medical STREAMWAY(R) Systems to Large University Hospital Organization
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY(R) System for…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q2 2020 Results, Business Update and DojoLIVE! Interview
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Thursday released financial results for the quarter ended June 30, 2020 and provided a business…
-
Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Members; Adds Depth of Knowledge, Experience to Strengthen Company’s Vision
Appointments signify POAI’s commitment to aligning board’s expertise with company’s strategic vision Board members to support development, commercialization of unique offering that improves outcomes for oncology patients, value to shareholders New appointments effective immediately Predictive…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shareholder Letter Highlights Achievements, Discusses Two Key Proposals
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, outlined the company’s recent accomplishments in a letter released to shareholders. The letter, sent from CEO…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Marks Milestone in Applying AI to Find New Targets for Treatment, Diagnostics
Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis and working with distributor US Biological Corporation, has accomplished a major achievement. Recently, the company announced its first-ever commercial order of a novel ovarian cancer cell culture…
-
Predictive Oncology Inc. (NASDAQ: POAI)’s TumorGenesis Presents at Precision in Drug Discovery & Preclinical Virtual Summit
TumorGenesis president Richard Gabriel selected to feature as keynote presenter at inaugural Drug Discovery & Preclinical Virtual Summit The summit features over 150 delegates from across bio-pharmaceutical industry coming together to market sector’s latest breakthroughs…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Integrate Proprietary Database with CoRE to Drive Drug Discovery, Development
Predictive Oncology (NASDAQ: POAI) has completed a strategic move to accelerate commercialization of its proprietary artificial intelligence “AI”-driven drug discovery and development. A recent article discussing Predictive Oncology’s recent acquisition of Quantitative Medicine (“QM”), a…
-
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Announces First Commercial Sale of Unique Ovarian-Cancer-Cell Media
POAI’s TumorGenesis inks deal with top-rated medical university in New England Predictive’s proprietary media allows researchers around the world to isolate, culture ovarian cancer cell types, leading to new targets for treatment The TumorGenesis media…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) on ‘Cash Runway’ to Fund Key Milestones
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is on a well-funded path to move forward with its goals. A recent article discussing this…
-
Predictive Oncology Inc. (NASDAQ: POAI) Finalizes Acquisition Deal Expected to Revolutionize Role of AI-Driven Predictive Models
POAI completes acquisition designed to accelerate commercialization of proprietary AI-driven drug discovery, development Strategic move allows for one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates Company to offer new capability to pharmaceutical…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Appointments
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of three new members to the company’s board of directors, effective immediately.…
-
Predictive Oncology Inc. (NASDAQ: POAI) Releases Q1 2020 Financial, Business Report; Revenues Up, Margins Stay Strong
POAI improved liquidity position, streamlined capital structure with conversion of $2.1 million convertible note Business highlights include continued initial study to sequence ovarian tumors, validate “reach-back” Company closed transaction resulting in gross cash proceeds of…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial